Renal safety of zoledronic acid for osteoporosis in adults 75 years and older

Fixen, Cy W; Fixen, Danielle R.

doi:10.1007/s00198-022-06499-4

Cited by 11 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this guidance has been questioned by a number of studies [ 21–23 ]. In a study of 558 infusions of IV Zol in 327 patients aged 75 years or older, Fixen et al .…”

Section: Methodsmentioning

confidence: 99%

“…In a study of 558 infusions of IV Zol in 327 patients aged 75 years or older, Fixen et al . reported that just eight (1.4%) experienced an acute kidney injury (AKI) in the following year, with creatinine levels all returning to within 0.1 mg/dl of baseline within the year [ 21 ]. All those who experienced an AKI not only had CrCl > 45 ml/min but also had known risk factors for Zol-induced nephrotoxicity, such as concurrent nephrotoxic medication and dehydration.…”

Section: Methodsmentioning

confidence: 99%

“…These studies recommended that infusions should be given over 30 min with eGFR < 50 ml/min [ 15 , 21 , 23 ]. Clinical data suggest that potential renal damage with IV Zol may be infusion-time-related and dose-related.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture

Johansen,

Sahota,

Dockery

et al. 2023

Age and Ageing

View full text Add to dashboard Cite

Currently in the UK and Ireland, after a hip fracture most patients do not receive bone protection medication to reduce the risk of refracture. Yet randomised controlled trial data specifically examining patients with hip fracture have shown that intravenous zoledronate reduces refracture risk by a third. Despite this evidence, use of intravenous zoledronate is highly variable following a hip fracture; many hospitals are providing this treatment, whilst most are currently not. A range of clinical uncertainties, doubts over the evidence base and practical concerns are cited as reasons. This paper discusses these concerns and provides guidance from expert consensus, aiming to assist orthogeriatricians, pharmacists and health services managers establish local protocols to deliver this highly clinically and cost-effective treatment to patients before they leave hospital, in order to reduce costly re-fractures in this frail population.

show abstract

“…However, this guidance has been questioned by a number of studies [ 21–23 ]. In a study of 558 infusions of IV Zol in 327 patients aged 75 years or older, Fixen et al .…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture

Johansen,

Sahota,

Dockery

et al. 2023

Age and Ageing

View full text Add to dashboard Cite

show abstract

Renal safety of zoledronic acid in patients with osteoporosis: a retrospective study

Ma,

Xu,

et al. 2023

Endocrine

View full text Add to dashboard Cite

IntroductionThis study aimed to investigate the renal safety of Zoledronic Acid (ZOL) in patients with osteoporosis (OP). MethodsA total of 1,523 patients with primary OP who received ZOL from January 2008 to October 2020 at our hospital were retrospectively analyzed. Baseline and one-year post-infusion renal function index data were analyzed in relation to clinical characteristics and comorbidities. Furthermore, the changes in renal function between a three-year consecutive infusion and a single infusion of ZOL were compared. ResultsIn our study, patients with diabetes mellitus had a signi cantly lower estimated glomerular ltration rate than those without after one year of ZOL infusion, and their creatinine (Cr) and cystatin C (CysC) levels were signi cantly higher (all P < 0.05). Patients with malignant tumors had a signi cantly lower estimated glomerular ltration rate and higher Cr levels than those without (all P < 0.05). CysC levels were signi cantly higher in patients aged 65 and older and those with hypertension than in their counterparts (all P < 0.05). No adverse renal events such as acute kidney injury were detected. There were no signi cant differences in renal function index between the three-year continuous infusion group and the single infusion group after one year of infusion(s) (all P > 0.05). ConclusionZOL infusion shows good renal safety in OP patients. Continuous infusion of ZOL did not exert a signi cant impact on renal function when compared to single infusion. However, the age of 65 years or older and comorbidities such as hypertension, diabetes mellitus, or malignant tumors may represent risk factors that predict adverse renal effects of ZOL infusion.

show abstract

Multiple drugs

2023

Reactions Weekly

View full text Add to dashboard Cite

Renal safety of zoledronic acid for osteoporosis in adults 75 years and older

Cited by 11 publications

References 16 publications

Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture

Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture

Renal safety of zoledronic acid in patients with osteoporosis: a retrospective study

Multiple drugs

Contact Info

Product

Resources

About